186 related articles for article (PubMed ID: 2883055)
21. Glucagon supports postabsorptive plasma glucose concentrations in humans with biologically optimal insulin levels.
Cooperberg BA; Cryer PE
Diabetes; 2010 Nov; 59(11):2941-4. PubMed ID: 20699417
[TBL] [Abstract][Full Text] [Related]
22. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.
Ryan AS; Egan JM; Habener JF; Elahi D
J Clin Endocrinol Metab; 1998 Jul; 83(7):2399-404. PubMed ID: 9661618
[TBL] [Abstract][Full Text] [Related]
23. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
Neuhaus C; Kerner W; Maier V; Pfeiffer EF
Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
[TBL] [Abstract][Full Text] [Related]
24. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14.
Hadjidakis DI; Raptis SA; Raptis AE; Karaiskos C; Souvatzoglou A; Diamantopoulos EJ
Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770
[TBL] [Abstract][Full Text] [Related]
25. Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycemia in type I diabetes. Evidence for an effect mediated by beta-adrenoreceptors.
Bolli G; de Feo P; Compagnucci P; Cartechini MG; Angeletti G; Santeusanio F; Brunetti P
Diabetes; 1982 Jul; 31(7):641-7. PubMed ID: 6298039
[TBL] [Abstract][Full Text] [Related]
26. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
27. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA
Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329
[TBL] [Abstract][Full Text] [Related]
28. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
29. Insulin-antagonistic effects of pulsatile and continuous glucagon infusions in man--a comparison with the effect of adrenaline.
Attvall S; Fowelin J; von Schenck H; Smith U; Lager I
J Clin Endocrinol Metab; 1992 May; 74(5):1110-5. PubMed ID: 1569157
[TBL] [Abstract][Full Text] [Related]
30. Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man.
Ward WK; Best JD; Halter JB; Porte D
J Clin Endocrinol Metab; 1984 Mar; 58(3):449-53. PubMed ID: 6141177
[TBL] [Abstract][Full Text] [Related]
31. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
32. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
Vella A; Shah P; Basu R; Basu A; Holst JJ; Rizza RA
Diabetes; 2000 Apr; 49(4):611-7. PubMed ID: 10871199
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs.
Sakurai H; Dobbs R; Unger RH
J Clin Invest; 1974 Dec; 54(6):1395-402. PubMed ID: 4436439
[TBL] [Abstract][Full Text] [Related]
34. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
Toft-Nielson M; Madsbad S; Holst JJ
Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
[TBL] [Abstract][Full Text] [Related]
35. Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
Nielsen MF; Wise S; Dinneen SF; Schwenk WF; Basu A; Rizza RA
Diabetes; 1997 Dec; 46(12):2007-16. PubMed ID: 9392488
[TBL] [Abstract][Full Text] [Related]
36. The glucoregulatory response to intravenous glucose infusion in normal man: roles of insulin and glucose.
Saccà L; Vitale D; Cicala M; Trimarco B; Ungaro B
Metabolism; 1981 May; 30(5):457-61. PubMed ID: 6112655
[TBL] [Abstract][Full Text] [Related]
37. Effects of amino acids on glucose disposal.
Boden G; Tappy L
Diabetes; 1990 Sep; 39(9):1079-84. PubMed ID: 1974539
[TBL] [Abstract][Full Text] [Related]
38. Increased action of pulsatile compared to non-pulsatile insulin delivery during a meal-like glucose exposure simulated by computerized infusion in healthy humans.
Juhl CB; Gjedsted J; Nielsen MF; Schmitz O
Metabolism; 2012 Aug; 61(8):1177-81. PubMed ID: 22386942
[TBL] [Abstract][Full Text] [Related]
39. Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin.
Sherwin RS; Hendler R; DeFronzo R; Wahren J; Felic P
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):348-52. PubMed ID: 264686
[TBL] [Abstract][Full Text] [Related]
40. Adrenergic blockade alters glucose kinetics during exercise in insulin-dependent diabetics.
Simonson DC; Koivisto V; Sherwin RS; Ferrannini E; Hendler R; Juhlin-Dannfelt A; DeFronzo RA
J Clin Invest; 1984 Jun; 73(6):1648-58. PubMed ID: 6327767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
